Epilepsy

In addition to a well-tolerated safety profile, investigators observed a dose proportional increase in plasma pharmacodynamics in the MONARCH study cohort of 21 children and adolescents.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 27, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.

The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

Reduced low-frequency power measured at rest was independently associated with an elevated SUDEP risk, presumably through arrhythmogenic mechanisms.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 20, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the FDA approval of cannabidiol as an oral solution for the treatment of seizures, specifically for both Dravet and Lennox-Gastaut syndromes.

Two experts detail the current treatment options for Dravet and Lennox-Gastaut syndromes and how they select which patients should use a specific drug.

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

In addition to changes in CCL2 levels, anxiety and health-related quality of life were both significantly increased in both the valproate and add-on levetiracetam groups.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.

Beginning enrollment in 2022, the NAUTILUS pivotal study will be the first in the United States to evaluate brain-responsive neuromodulation in patients with idiopathic generalized epilepsy.

Drs Thiele and Wirrell explain how clinicians diagnose patients with Dravet or Lennox-Gastaut syndromes and the typical triggers patients will exhibit.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the commonality of childhood epilepsies, as well as the differences between Dravet syndrome and Lennox-Gastaut syndrome.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the critical findings on how heart rate variability may stratify individual SUDEP risk. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive.

A stronger association between the 2 conditions was seen in younger patients and men with epilepsy than their counterparts in the matched cohort of more than 9000 individuals.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.